Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Timothy E. Schlub Clear advanced filters

  • Here, based on a systematic review and meta-analysis, the authors analyze the relationship between vaccine immunogenicity and vaccine protection against mpox and predict the durability of protection after vaccination. This helps inform the optimal vaccine deployment in a health emergency.

    • Matthew T. Berry
    • Shanchita R. Khan
    • David S. Khoury
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-11

  • SARS-CoV-2 vaccines have been updated to include antigens from new variants. Here, the authors analyse data from published studies to investigate whether updating vaccines provides additional immunity to subsequent emerging strains compared to using original vaccines.

    • Deborah Cromer
    • Arnold Reynaldi
    • Miles P. Davenport
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-9

  • Monoclonal antibodies (mAbs) have shown efficacy against SARS-CoV-2 infection in clinical trials. Here the authors model the dose-response relationship between the dose of mAbs and protection from symptomatic SARS-CoV-2 infection. Further, the protection is comparable to that achieved by vaccination.

    • Eva Stadler
    • Martin T. Burgess
    • David S. Khoury
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-9

  • In this study, the authors perform a meta-analysis of COVID-19 vaccine effectiveness studies and compare observed protection against severe disease with model-based estimates of neutralising antibody titres. Their results show that SARS-CoV-2 antibody titres are predictive of protection against severe COVID-19 disease.

    • Deborah Cromer
    • Megan Steain
    • Miles P. Davenport
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-9

  • Longitudinal analyses are needed to show how the immune response to Sars-Cov-2 infection changes over time. Here, the authors use multiple strategies to profile the change in immune cell responses from patients with convalescent COVID-19 over the course of ~5 months, showing that although neutralizing antibody responses drop off after ~4 months, B cell immune responses strengthen.

    • Adam K. Wheatley
    • Jennifer A. Juno
    • Stephen J. Kent
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-11

  • Understanding the resistance of natural hosts of simian immunodeficiency virus (SIV)—such as sooty mangabeys—to disease progression may yield insights applicable to HIV-1. In this issue, Paiardini et al. report that CD4+ central memory T (TCM) cells from sooty mangabeys do not strongly upregulate CCR5 upon activation and are more resistant to SIV infection than TCM cells from rhesus macaques, which may contribute to proper immune control and prevention of disease in these natural hosts.

    • Mirko Paiardini
    • Barbara Cervasi
    • Guido Silvestri
    Research
    Nature Medicine
    Volume: 17, P: 830-836